NAPA, Calif., March 27 /PRNewswire-FirstCall/ -- Senetek PLC , a life sciences product development company targeting the science of aging, today announced that the Company maintained a booth and made a short presentation at the 5th installment of the ValueRich Small-Cap Financial Expo at the Hotel InterContinental, Miami, Florida, on March 27th. A replay of the webcast is available at http://www.vrexpo.net.
“We are extremely excited about this opportunity to reach a large and diverse group of existing and potential investors,” said Mr. Frank J. Massino, Senetek’s chairman and chief executive officer. “We believe that the Senetek story offers a unique investment opportunity to the buy-side community, and we look forward to introducing our diverse intellectual property portfolio to a wider audience.”
Hosted by ValueRich Inc., the expo is a two-day event featuring rapidly growing small-cap companies, and giving them the opportunity to present their business plans and showcase their products and services in an expo-style format to a diverse array of buy-side professionals. Following the presentation, Mr. Bill O’Kelly, Senetek’s Chief Financial Officer, met one-on-one with analysts and investors. Please visit http://www.vrexpo.net for more information.
About Senetek PLC
Senetek PLC is a life sciences product development company with a portfolio of intellectual properties targeting the science of aging, including skincare and dermatological therapeutics, erectile dysfunction and nutrition. Kinetin, Senetek PLC’s lead commercial product, is currently licensed and marketed by 14 pharmaceutical and cosmeceutical companies, including Valeant Pharmaceuticals International and The Body Shop. In addition, the Company has entered into an exclusive global license with Valeant for Senetek’s proprietary anti-aging skincare compound, Zeatin, has entered into exclusive licenses for Europe and North America, respectively, for its patented combination drug treatment for erectile dysfunction, Invicorp(R), has an exclusive manufacturing distributorship for its proprietary diagnostic monoclonal antibodies, and recently sold, with retained rights of profit participation, its patented drug delivery system, Reliaject(R).
For more information, visit the company’s website at http://www.senetekplc.com/
This news release contains statements that may be considered ‘forward-looking statements’ within the meaning of the Private Securities Litigation Reform Act, including those that might imply commercial potential and successful evaluation and development of new compounds. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company’s Annual Report on Form 10-K/A for the year 2005. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
This document is available on the KCSA Worldwide Website at http://www.kcsa.com. For Senetek PLC Investor Contacts: KCSA Worldwide Todd Fromer / Garth Russell 212-896-1215 / 212-896-1250 tfromer@kcsa.com / grussell@kcsa.com
Senetek PLC
CONTACT: Investor: Todd Fromer, +1-212-896-1215, tfromer@kcsa.com, orGarth Russell, +1-212-896-1250, grussell@kcsa.com, both of KCSA Worldwide,for Senetek PLC
